| Literature DB >> 32452650 |
Andrea Casiraghi1,2, Francesca Longhena3, Valentina Straniero1, Gaia Faustini3, Amy H Newman2, Arianna Bellucci3, Ermanno Valoti1.
Abstract
We previously described synapsin III (Syn III) as a synaptic phosphoprotein that controls dopamine release in cooperation with α-synuclein (aSyn). Moreover, we found that in Parkinson's disease (PD), Syn III also participates in aSyn aggregation and toxicity. Our recent observations point to threo-methylphenidate (MPH), a monoamine re-uptake inhibitor that efficiently counteracts the freezing-gait characteristic of advanced PD, as a ligand for Syn III. We have designed and synthesised two different fluorescently labelled MPH derivatives, one with Rhodamine Red (RHOD) and one with 5-carboxytetramethylrhodamine (TAMRA), to be used for assessing MPH binding to Syn III by FRET. TAMRA-MPH exhibited the ideal characteristics to be used as a FRET acceptor, as it was able to enter into the SK-N-SH cells and could interact specifically with human green fluorescent protein (GFP)-tagged Syn III but not with GFP alone. Moreover, the uptake of TAMRA-MPH and co-localization with Syn III was also observed in primary mesencephalic neurons. These findings support that MPH is a Syn III ligand and that TAMRA-conjugated drug molecules might be valuable tools to study drug-ligand interactions by FRET or to detect Syn III in cytological and histological samples.Entities:
Keywords: FRET; Parkinson's disease; Synapsin III binding; TAMRA; methylphenidate
Mesh:
Substances:
Year: 2020 PMID: 32452650 PMCID: PMC7486004 DOI: 10.1002/cmdc.202000128
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.540